D-Serine

Generic Name: D-Serine

Drug Type: Small Molecule

Chemical Formula: C_₃H_₇NO_₃

CAS Number: 312-84-5

Unique Ingredient Identifier: 1K77H2Z9B1

Background: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids. [PubChem]

Clinical Trials

D-serine AudRem: R33 Phase

Phase 1

Suspended

Conditions: Schizophrenia
Schizo Affective Disorder

Interventions: Other: Placebo
Drug: D-serine

First Posted Date: 2021-09-16

Last Posted Date: 2025-05-13

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 60

Registration Number: NCT05046353

Locations: 🇺🇸
NYSPI, New York, New York, United States

A Study to Compare the Safety, Tolerability, and Pharmacokinetics of CTP-692 Versus D-serine in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CTP-692
Drug: D-Serine

First Posted Date: 2018-12-19

Last Posted Date: 2019-03-15

Lead Sponsor: Concert Pharmaceuticals

Target Recruit Count: 13

Registration Number: NCT03778320

Locations: 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia

D-serine Augmentation of Neuroplasticity

Phase 1

Completed

Conditions: Schizophrenia
Schizo Affective Disorder

Interventions: Drug: D-serine
Drug: Placebo

First Posted Date: 2018-10-18

Last Posted Date: 2022-06-14

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 45

Registration Number: NCT03711500

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
🇺🇸
Nathan Kline Institute, Orangeburg, New York, United States

D-serine and Cognitive Remediation in Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: D-serine

First Posted Date: 2014-06-05

Last Posted Date: 2020-10-08

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 8

Registration Number: NCT02156908

Locations: 🇺🇸
Nathan Kline Institute, Orangeburg, New York, United States

D-Serine for Cocaine Dependence Pilot

Phase 2

Withdrawn

Conditions: Cocaine Dependence

Interventions: Drug: D-serine
Behavioral: Cognitive Behavioral Therapy
Drug: Placebo

First Posted Date: 2012-10-26

Last Posted Date: 2014-02-06

Lead Sponsor: Theresa Winhusen

Registration Number: NCT01715051

Locations: 🇺🇸
Maryhaven, Inc, Columbus, Ohio, United States

N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia

Phase 2

Conditions: Schizoaffective Disorder
Schizophrenia

Interventions: Drug: placebo
Drug: D-serine
Behavioral: Sensory Based remediation paradigm

First Posted Date: 2011-11-18

Last Posted Date: 2012-10-25

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 16

Registration Number: NCT01474395

Locations: 🇺🇸
Nathan Kline Insitute for Psychiatric Research, Orangeburg, New York, United States

High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia

Phase 2

Conditions: Schizophrenia

Interventions: Drug: D-serine

First Posted Date: 2011-10-25

Last Posted Date: 2011-10-25

Lead Sponsor: Hadassah Medical Organization

Target Recruit Count: 54

Registration Number: NCT01459029

Locations: 🇮🇱
Ezrath Nashim - Herzog Memorial Hospital & Community Clinics, Jerusalem, Israel
🇮🇱
Hadassah Medical Organization, Jerusalem, Israel

Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission

Phase 4

Completed

Conditions: Tourette Syndrome

Interventions: Drug: Placebo
Drug: Riluzole
Drug: D-serine

First Posted Date: 2009-11-23

Last Posted Date: 2018-01-30

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 39

Registration Number: NCT01018056

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

D-serine for the Schizophrenia Prodrome

Phase 2

Completed

Conditions: Schizophrenia Prodrome

Interventions: Drug: D-serine
Other: Placebo

First Posted Date: 2009-01-22

Last Posted Date: 2017-08-14

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 44

Registration Number: NCT00826202

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
Zucker Hillside Hospital, Glen Oaks, New York, United States
🇺🇸
New York State Psychiatric Institute, New York, New York, United States

and more 1 locations

D-serine Monotherapy for Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: D-serine
Drug: Olanzapine

First Posted Date: 2009-01-05

Last Posted Date: 2013-12-10

Lead Sponsor: Herzog Hospital

Target Recruit Count: 18

Registration Number: NCT00816894

Locations: 🇮🇱
Ezrath Nashim - Herzog Memorial Hospital, Jerusalem, Israel

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy